Oculus Optikgeraete GMBH Munchholzhauser Str. 29 Wetzlar Germany Oculus Myopia Master , Ref 68100, CE 0123 Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Oculus Myopia Master , Ref 68100, CE 0123
Brand
Oculus Optikgeraete GMBH Munchholzhauser Str. 29 Wetzlar Germany
Lot Codes / Batch Numbers
UDI-DI, (01) 04049584026095
Products Sold
UDI-DI; (01) 04049584026095
Oculus Optikgeraete GMBH Munchholzhauser Str. 29 Wetzlar Germany is recalling Oculus Myopia Master , Ref 68100, CE 0123 due to Their is a potential that optical devices with insufficient anti-reflective coating may lead to incorrect axial length measurements.. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Their is a potential that optical devices with insufficient anti-reflective coating may lead to incorrect axial length measurements.
Recommended Action
Per FDA guidance
On August 04, 2023, Oculus issued a Urgent Field Safety Notice" Correction via UPS Express. Oculus ask consignees to take the following actions: 1. Immediately stop using the affected devices for axis length measurement (mark the affected devices with a note) or take them out of service immediately. Devices not listed in Appendix B are not affected by this corrective action and can continue to be used according to the instructions for use. 2. Please fill out the attached form (Appendix A) and return it to OCULUS and your local OCULUS representative as soon as possible, but no later than 30 days after receipt. By completing this form, you acknowledge receipt of the Urgent Field Safety Notice and that you understand the issue and the actions required. 3. Pass this urgent safety information on to all users of the affected products and other people who need to be informed so that they are aware of the problem. Please file this letter directly with your device and make sure that it is and remains visible to all users at the storage location. It is important that the meaning of this notification is understood. 4. If you have given the products to a third party, please forward a copy of this information immediately and please inform us accordingly. 5. Please keep this urgent safety information at least until the action has been completed.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026